Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory ... - Nature
"... thyroid cancer. Three parallel cohorts including patients with differentiated thyroid carcinoma (Cohort 1, n = 37), medullary thyroid carcinoma ..."